[go: up one dir, main page]

EE9600057A - Flaviini derivaadid viirusvastaste toimeainetena kasutamiseks - Google Patents

Flaviini derivaadid viirusvastaste toimeainetena kasutamiseks

Info

Publication number
EE9600057A
EE9600057A EE9600057A EE9600057A EE9600057A EE 9600057 A EE9600057 A EE 9600057A EE 9600057 A EE9600057 A EE 9600057A EE 9600057 A EE9600057 A EE 9600057A EE 9600057 A EE9600057 A EE 9600057A
Authority
EE
Estonia
Prior art keywords
antiviral agents
flavin derivatives
flavin
derivatives
antiviral
Prior art date
Application number
EE9600057A
Other languages
English (en)
Inventor
Ayuko Washington Odur
Original Assignee
Radopath Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radopath Limited filed Critical Radopath Limited
Publication of EE9600057A publication Critical patent/EE9600057A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EE9600057A 1993-10-19 1994-10-19 Flaviini derivaadid viirusvastaste toimeainetena kasutamiseks EE9600057A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents
PCT/GB1994/002292 WO1995011028A1 (en) 1993-10-19 1994-10-19 Flavin derivatives as anti-viral agents

Publications (1)

Publication Number Publication Date
EE9600057A true EE9600057A (et) 1996-10-15

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600057A EE9600057A (et) 1993-10-19 1994-10-19 Flaviini derivaadid viirusvastaste toimeainetena kasutamiseks

Country Status (26)

Country Link
EP (1) EP0739208A1 (et)
JP (1) JPH09505804A (et)
CN (1) CN1140992A (et)
AP (1) AP620A (et)
AU (1) AU7943794A (et)
BG (1) BG100599A (et)
BR (1) BR9407862A (et)
CA (2) CA2123825A1 (et)
CO (1) CO4520283A1 (et)
CZ (1) CZ113796A3 (et)
EE (1) EE9600057A (et)
GB (2) GB9321558D0 (et)
HR (1) HRP940688A2 (et)
HU (1) HUT76322A (et)
IL (1) IL111338A0 (et)
JO (1) JO1866B1 (et)
MA (1) MA23356A1 (et)
MD (1) MD960168A (et)
NO (1) NO961547L (et)
OA (1) OA10579A (et)
PE (1) PE5596A1 (et)
PL (1) PL314008A1 (et)
SK (1) SK50696A3 (et)
UY (1) UY23844A1 (et)
WO (1) WO1995011028A1 (et)
ZA (1) ZA948191B (et)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
EP1531823A4 (en) * 2002-05-10 2007-07-18 Univ Ohio State FLAVIN N-OXIDE: NEW CANCER AND MEANS TO REMOVE ENTANGERS
ITTO20020622A1 (it) 2002-07-16 2004-01-16 Dayco Europe Srl Gruppo integrato puleggia-smorzatore torsionale
WO2004013142A1 (en) * 2002-08-02 2004-02-12 The Institute Of Radiation Medicine, Academy Of Miilitary Medical Sciences, People's Liberation Army A riboflavin derivative and its manufacture and uses
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem
JP2018131410A (ja) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 カスパーゼ−３阻害剤とその用途
CU20200039A7 (es) * 2017-10-24 2021-03-11 Lunella Biotech Inc Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocrondrial
KR20220034163A (ko) * 2019-07-09 2022-03-17 디에스엠 아이피 어셋츠 비.브이. 엘라피브라노와 리보플라빈 또는 dha의 바이러스 활성 감소

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
AU3222893A (en) * 1991-11-25 1993-06-28 University Of Michigan, The Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (ja) * 1992-03-27 2000-08-07 雪印乳業株式会社 シアル酸結合５−デアザフラビン系化合物

Also Published As

Publication number Publication date
HRP940688A2 (en) 1997-04-30
GB2283913A (en) 1995-05-24
AP9400695A0 (en) 1995-01-31
JO1866B1 (en) 1995-12-27
CN1140992A (zh) 1997-01-22
ZA948191B (en) 1995-06-08
CZ113796A3 (en) 1996-11-13
MD960168A (ro) 1998-04-30
MA23356A1 (fr) 1995-07-01
WO1995011028A1 (en) 1995-04-27
GB9321558D0 (en) 1993-12-08
EP0739208A1 (en) 1996-10-30
PL314008A1 (en) 1996-08-05
PE5596A1 (es) 1996-04-18
JPH09505804A (ja) 1997-06-10
IL111338A0 (en) 1994-12-29
BR9407862A (pt) 1997-05-20
GB9421099D0 (en) 1994-12-07
AP620A (en) 1997-10-14
HUT76322A (en) 1997-08-28
UY23844A1 (es) 1995-03-28
BG100599A (en) 1997-02-28
OA10579A (en) 2002-06-19
CA2174552A1 (en) 1995-04-27
CA2123825A1 (en) 1995-04-20
SK50696A3 (en) 1997-01-08
HU9601006D0 (en) 1996-06-28
NO961547L (no) 1996-06-19
AU7943794A (en) 1995-05-08
NO961547D0 (no) 1996-04-18
CO4520283A1 (es) 1997-10-15

Similar Documents

Publication Publication Date Title
FI954727L (fi) Uusia virusvastaisia yhdisteitä
DE69325333D1 (de) Antivirale Zusammensetzung
FI930208L (fi) Kinazolinderivat
FI935431A7 (fi) Kiantsoliinijohdannaisia
FI980341A7 (fi) 2-oksi-indolijohdannaisia
FI893618A7 (fi) Antibakteerisina aineina käyttökelpoisia amino-metyyliokso-oksatsolidinyyliaryylibentseeni-johdannaisia
FI943976A7 (fi) 5-aryyli-indolijohdannaiset
FI941423A7 (fi) 17beta-substituoidut 4-atsa-5alfa-androstan-3-onijohdannaiset
FI945674L (fi) Substituoidut 2beta-morfoliini-androstaanijohdannaiset
FI20010214A7 (fi) Asyyliaminoindolijohdannaisia
FI940167L (fi) Puriinijohdannaisia
EE9600057A (et) Flaviini derivaadid viirusvastaste toimeainetena kasutamiseks
FI942444A7 (fi) Terahydropyraanijohdannaisia
FI940166A0 (fi) Uusia adenosiinijohdannaisia
FI943885L (fi) Penaami-johdannaiset
FI20002460A7 (fi) 4-difenyylimetyylipiperidiinijohdannaisia
FI895447A7 (fi) Substituoidut terapeuttisina aineina käytettävät adeniinijohdannaiset
FI944044L (fi) Fenyylialkanoliamiinijohdannaiset
FI953127L (fi) Puriinijohdannaisia
NO970158D0 (no) Difluorstaton-antivirale midler
NO952288D0 (no) Benzazepinon-derivater
FI972585A7 (fi) Virustenvastaisina aineina käyttökelpoiset tienoksatsinonijohdannaiset
EP0583161A3 (en) 4-aminopyrrole-2-carboxamide derivatives as antiviral agents
FI911310A7 (fi) Substituoidut puriinit, menetelmä niiden valmistamiseksi, sekä niiden käyttö antiviraalisina aineina
FI953106A7 (fi) Difuoripentapeptidijohdannaiset anti-inflammatorisina aineina